Ozanimod - Receptos

Drug Profile

Ozanimod - Receptos

Alternative Names: Ozanimod-HCl; RPC-1063; RPC-1063-HCl

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Scripps Research Institute
  • Developer Celgene Corporation; Receptos
  • Class Antiulcers; Indenes; Nitriles; Oxadiazoles; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Phase III Multiple sclerosis; Ulcerative colitis
  • Phase II Crohn's disease

Most Recent Events

  • 28 Oct 2017 Celgene intends to submit MAA to the EMA for Multiple sclerosis in 1H 2018
  • 28 Oct 2017 Efficacy and adverse events data from the phase III portion (Part B) of the phase II/III RADIANCE trial in Multiple sclerosis presented at the 7th Joint ECTRIMS – ACTRIMS Meeting 2017
  • 27 Oct 2017 Safety and efficacy data from the phase III SUNBEAM trial in Multiple sclerosis presented at the 7th Joint ECTRIMS – ACTRIMS Meeting 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top